Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 11/28/2014 8:47:02 AM - Followers: 161 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Statement of Changes in Beneficial Ownership (4) 11/07/2014 02:58:41 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 11/05/2014 09:27:10 AM
CVM News: CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial 11/03/2014 08:30:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/28/2014 04:49:23 PM
CVM News: CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million 10/24/2014 10:09:00 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6432   Exactly. Management dictates the reverse split. Management still peterose 11/28/14 08:47:01 AM
#6431   Personally. I wait for something exceptional to catch learning curve 11/27/14 11:53:38 PM
#6430   Edit; becuase you have faith or believe in learning curve 11/27/14 11:45:17 PM
#6429   Your agreememt with my first point is the learning curve 11/27/14 11:43:28 PM
#6428   A R/S would be a death mark for Foxwoods Man 11/27/14 07:47:50 PM
#6427   and with geert getting 2,100,000 gifted shares, a peterose 11/27/14 02:43:29 PM
#6426   They could do another r/s to get the peterose 11/27/14 02:40:00 PM
#6425   Am holding back as we'll at present. drkazmd65 11/27/14 01:48:39 PM
#6424   My point is without an arbitration award they peterose 11/27/14 01:01:45 PM
#6423   The R/S was not to get cash but Foxwoods Man 11/27/14 10:09:04 AM
#6422   I don't think they are going to do majatamata 11/27/14 09:47:51 AM
#6421   I agree with your 1st point. That always Foxwoods Man 11/27/14 08:07:05 AM
#6420   No arbitration award no doubt r/s on the peterose 11/27/14 12:24:02 AM
#6419   One thing that I never forget here is learning curve 11/26/14 10:51:01 PM
#6418   Cel-sci only needs 784 reviewable patients out of peterose 11/26/14 06:51:36 PM
#6417   I understand your point but that worldwide nebulous Foxwoods Man 11/26/14 04:59:44 PM
#6416   but my point is that the control group kurious 11/26/14 04:55:31 PM
#6415   That's the way randomized studies work...there is always Foxwoods Man 11/26/14 04:17:09 PM
#6414   But aren't there already thousands of H&N cancer kurious 11/26/14 03:34:27 PM
#6413   I was tempted to add shares but held Foxwoods Man 11/26/14 03:23:43 PM
#6412   Got bored bought 10000 more options .1461 the Turney 11/26/14 02:39:30 PM
#6411   Correct..they are the control group which the results Foxwoods Man 11/26/14 09:29:34 AM
#6410   Even though group 1 doesn't get thing but Turney 11/26/14 09:24:42 AM
#6409   No prob... Foxwoods Man 11/26/14 08:47:56 AM
#6408   Correct me if I'm wrong but SOC is Turney 11/26/14 08:36:44 AM
#6407   Except you missed the actual Standard of care Foxwoods Man 11/26/14 07:30:44 AM
#6406   The design of the trial is as follows; Turney 11/26/14 06:52:27 AM
#6405   I couldn't add this from my phone last night: Foxwoods Man 11/26/14 06:50:36 AM
#6404   Standard of care is maintained for the study. Foxwoods Man 11/25/14 09:58:42 PM
#6403   I'm confused...turney said what I thought to be true.... learning curve 11/25/14 09:53:41 PM
#6402   I would like to know that as well; learning curve 11/25/14 09:48:49 PM
#6401   I believe it is not a double blind kurious 11/25/14 09:32:13 PM
#6400   Correct...they both get the standard of care Foxwoods Man 11/25/14 12:53:48 PM
#6399   I think half of the study gets just Turney 11/25/14 12:52:22 PM
#6398   I would think their eventual goal after approval Foxwoods Man 11/25/14 10:07:58 AM
#6397   I would agree FM. If it was drkazmd65 11/25/14 09:56:27 AM
#6396   ...and the fact that Multikinefor the study is Foxwoods Man 11/25/14 06:55:58 AM
#6395   That's nice logic, but where do results stand; learning curve 11/24/14 09:41:07 PM
#6394   The reason CVM is having slow going in Turney 11/24/14 08:56:34 PM
#6393   Thanks...I needed that. Foxwoods Man 11/24/14 07:03:03 AM
#6392   Here is a nice article from 9/11... majatamata 11/23/14 07:43:33 PM
#6391   If CVM has 1/2 a brain...which I am kurious 11/23/14 06:47:08 PM
#6390   Googled arbitration. Complex issues 12-15 months. Then 30 peterose 11/23/14 12:09:57 PM
#6389   Excellent question. ..no clue about the answer Foxwoods Man 11/22/14 03:25:26 PM
#6388   When do you think any prelims will be majatamata 11/22/14 03:19:31 PM
#6387   Correct on the filing. That's what peterrose posted Foxwoods Man 11/22/14 02:51:30 PM
#6386   CEL SCI CORP NT 10-K 12/17/2013 9/30/2013 View this majatamata 11/22/14 02:31:26 PM
#6385   Nice find... Foxwoods Man 11/22/14 08:02:58 AM
#6384   Looks like cel-sci this time last year only peterose 11/22/14 07:52:28 AM
#6383   For whatever reason the nt 10-Q should have Foxwoods Man 11/22/14 07:51:41 AM
PostSubject